Cognition, Age and Rapamycin Effectiveness-Downregulation of the mTor Pathway (CARPE DIEM) Study

The purpose of this study is to evaluate if if the drug, Rapamycin, will reach the brain and effectively treat symptoms of Alzheimer’s disease and mild cognitive impairment using cerebrospinal fluid.

This drug therapy has shown to improve cerebral blood flow, decrease neuroinflammation and enhance memory in Alzheimer’s mouse models.

Eligibility

• Adults, ages 55 to 85, diagnosed with mild cognitive impairment or early stages of Alzheimer’s disease

Participation in the clinical trial includes completion of 8 study visits across 12 to 18 weeks.

Pre- and post-treatment assessments include lumbar puncture, laboratory blood work and thinking, mood, sleep and physical and sensory functioning evaluations.

There is no cost to participate in the study.